When diagnosed with metastatic pancreatic cancer, a patient faces unfavorable odds. Maintaining real hope is difficult when only 9 percent of patients survive five years.
But there is a place where hope lives, and that’s under the care of a clinical trial. Research has shown that the average one-year survival rate for metastatic patients is nearly double for those enrolled in a clinical trial.
Destroy Pancreatic Cancer’s laser-focused mission is to fund clinical trials in Atlanta.
In collaboration with The Translational Genomics Research Institute (TGen) and Piedmont Cancer Institute, Destroy Pancreatic Cancer is funding one of six, concurrent clinical trials. TGen is the undisputed leader in discovering advances that lead to new standard of care.